Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone
Year: 2026
Type: article
Source: Journal of Clinical Oncology
DOI: 10.1200/jco-26-00384
Authors: Pieter Sonneveld, Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Philippe Moreau, Hermann Einsele, Mario Boccadoro, Fredrik Borgsten, Andras Borsi, Marjorie Nobrega, Viktor Kovács, Jianping Wang, Melissa Rowe, Anna Sitthi-Amorn, Robin L. Carson, Meletios A. Dimopoulos, Paula Rodríguez-Otero, Saad Z. Usmani
Institutions: Erasmus MC Cancer Institute, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Université de Lille, Centre Hospitalier Universitaire de Lille, São Germano Oncologia, University of Calgary, Centre Hospitalier Universitaire de Nantes, Nantes Université, Universitätsklinikum Würzburg, Johnson & Johnson (United States), Johnson & Johnson (United Kingdom), Korea University, National and Kapodistrian University of Athens, Clinica Universidad de Navarra, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7225615455